Could a Cancer Drug Hold the Key to Slowing Parkinson’s?

A recent discovery has opened an exciting new path in Parkinson’s research, suggesting that an already FDA-approved drug could potentially slow down the disease. Scientists have been studying how harmful protein clumps, called alpha-synuclein, spread from one brain cell to another. These clumps are a major driver of Parkinson’s progression, affecting movement, speech, balance, and more. Researchers found that two proteins on brain cells, called Aplp1 and Lag3, act like entry points, helping the toxic alpha-synuclein get inside healthy neurons. In experiments with mice, blocking both proteins dramatically reduced the spread of these harmful clumps — by up to 90 percent compared with blocking just one protein. The particularly exciting part is that an existing cancer drug, which targets Lag3, also interferes with its interaction with Aplp1. In mouse models, this drug nearly completely stopped the toxic protein clumps from spreading between neurons. While it’s early days, the findings suggest a ready-made treatment could be repurposed to slow Parkinson’s progression. The research team is now planning further tests, including on models of Parkinson’s and Alzheimer’s, to see how effective the approach could be. While it’s not yet a proven therapy for humans, the work gives hope that understanding these protein interactions could lead to treatments that protect brain cells and slow the disease before major symptoms develop. This discovery highlights a shift in thinking: instead of only treating symptoms, scientists are targeting the underlying mechanisms that drive Parkinson’s forward. For people with the condition, it’s an encouraging step toward therapies that could make a real difference in daily life and long-term outcomes.